Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time they entered the study
- People diagnosed with a type of kidney cancer called papillary renal cell carcinoma (PRCC) that cannot be surgically removed and has either spread locally or to other parts of the body, or people diagnosed with kidney cancer where the main cancer type is at least 50% papillary in nature
- People who received one of two specific medications — sunitinib or sorafenib — as their first treatment for this cancer
- People who had a tumour assessment or relevant medical visit within 6 months of entering the study (people who passed away within that 6-month period may still be included)
Who may not be able to join:
- People whose kidney cancer is a specific type called papillary urothelial carcinoma or renal pelvis cancer
- People who have had another separate cancer in the past, unless that cancer was treated with the intent to cure and there has been no known active disease for 5 or more years
- People who received systemic cancer treatment for PRCC before entering the study, with some exceptions: treatment given before or after surgery is acceptable if it finished more than 12 months before the cancer spread or came back; if that pre/post-surgery treatment was given within 12 months before the cancer spread or returned, it will be counted as the first treatment instead; and people whose first treatment lasted 3 days or fewer may still be considered (confirm with trial site)
- People whose records are missing both the day and month of their study entry date
- People who had severe side effects or health conditions rated at grade 3 or higher (a medical severity scale) at the time of joining the study
- People who received sunitinib or sorafenib combined with any other cancer treatment — such as chemotherapy, other targeted therapies, or immunotherapy — as their first treatment
- People who meet additional exclusion criteria based on a related study called SAMETA, where this information can be clearly identified in their medical records (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: DingWei Ye, Postdoctoral, Fudan University
Phone: 1-877-240-9479
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary objective is to characterize the real-world PFS (rwPFS) with either sunitinib or sorafenib.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.